- Global Operation
- Contract Manufacturing
Cytarabine Injection, an antineoplastic, is a sterile solution of cytarabine for intravenous, intrathecal or subcutaneous
administration. Cytarabine is rapidly metabolized and is not effective orally; less than 20 percent of the orally administered dose is absorbed from the gastrointestinal tract.
Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found
useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia.
CytaraÂ® Injection 100 mg: Box containing 1 vial in plastic tray.
CytaraÂ® Injection 500 mg: Box containing 1 vial in plastic tray.
CytaraÂ® Injection 1000 mg: Box containing 1 vial in plastic tray.